Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Stoke Therapeutics Inc (NASDAQ:STOK) is set to release its Q2 2025 earnings on Aug 12, 2025. The consensus estimate for Q2 ...

Wrexham striker Ollie Palmer has scored two goals in the space of a minute in stoppage time then converted one of the team’s ...

BTIG analyst Thomas Shrader lowered the firm’s price target on Stoke Therapeutics (STOK) to $28 from $29 and keeps a Buy rating on the shares. The ...

Football Association of Wales (FAW) chief executive Noel Mooney has revealed the "legacy" role of Wrexham owners Ryan ...

Stoke Therapeutics, Inc. STOK announced that the FDA has granted a Breakthrough Therapy designation to its investigational candidate, zorevunersen (STK-001), for the treatment of Dravet syndrome ...

Here are some of the largest recent moves: FMR LLC added 2,376,741 shares (+1438.7%) to their portfolio in Q1 2025, for an estimated $15,805,327 MARSHALL WACE, LLP added 1,180,351 shares (+124.1% ...

Wrexham have released images of revised plans for a new Kop stand at their Stok Racecourse home. Revised designs for the new 5,500-capacity Kop Stand have been presented to Wrexham County Borough ...

STOK Company Profile Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.

STOK has a tiny market cap of $629.50 million and a rather large “short interest” of more than 21%. Last quarter the company saw a nice beat on both earnings ($1.90) and revenues ($158 million ...

Wrexham's Racecourse Ground will be renamed the SToK Racecourse for next season in a deal that sees the world's oldest international stadium have a title sponsor for the first time. The stadium ...

Wrexham ’s Racecourse Ground will have a new name next season for the second time in its history following a lucrative sponsorship deal that is expected to earn the club a substantial seven ...